What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 (glucose-dependent insulinotropic polypeptide / glucagon-like peptide-1) receptor agonist. It is the first peptide to target both incretin receptors simultaneously, representing a novel approach to metabolic research.
The dual mechanism allows tirzepatide to leverage the complementary effects of both GIP and GLP-1 pathways. Research has shown synergistic effects on insulin secretion, glucagon regulation, appetite control, and energy metabolism.
The 5mg vial is ideal for initial titration phases where lower doses are used for the first several weeks.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 5mg |
| Recommended BAC Water | 1mL |
| Resulting Concentration | 5mg/mL (5000mcg/mL) |
| Typical Research Dose | 2.5mg - 15mg weekly |
| Frequency | Once weekly |
| Research Duration | 20-72 weeks |
Reconstitution Guide
Materials Needed
- Tirzepatide 5mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.
-
Clean the vial stoppers — Wipe the Tirzepatide vial stopper and BAC water vial with alcohol swabs. Allow to dry.
-
Draw the BAC water — Using a sterile syringe, draw 1mL of bacteriostatic water.
-
Add water to peptide vial — Insert the needle and slowly inject BAC water down the inside wall of the vial. Never spray directly onto the powder.
-
Allow to dissolve — Tirzepatide typically dissolves within 5-10 minutes. Gently swirl if needed — never shake.
-
Verify dissolution — Solution should be clear and colorless. Discard if cloudy or particles visible.
-
Label and store — Write reconstitution date on vial. Refrigerate immediately.
Alternative Reconstitution Options
| BAC Water | Concentration | Best For |
|---|---|---|
| 1mL | 5mg/mL | Standard concentration |
| 2mL | 2.5mg/mL | Lower doses, more precision |
| 0.5mL | 10mg/mL | Smaller injection volumes |
Dosage Protocol
Concentration Calculations
With 5mg peptide in 1mL BAC water:
- Concentration: 5mg/mL = 5000mcg/mL
- Per unit (U-100 syringe): 50mcg per unit
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 2.5mg | 0.50mL | 50 units |
| 5.0mg | 1.00mL | 100 units (full vial) |
Note: The 5mg vial is best suited for the initial 2.5mg titration phase. For higher doses, consider 10mg or 30mg vials.
Doses Per Vial
At 5mg/mL concentration (1mL total = 5mg):
| Weekly Dose | Doses Per Vial | Duration |
|---|---|---|
| 2.5mg | 2 doses | 2 weeks |
| 5.0mg | 1 dose | 1 week |
Suggested Titration Protocol
Tirzepatide research protocols employ gradual escalation:
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 2.5mg | Initial titration (5mg vial ideal) |
| 5-8 | 5mg | First escalation |
| 9-12 | 7.5mg | Second escalation |
| 13-16 | 10mg | Third escalation |
| 17-20 | 12.5mg | Fourth escalation |
| 21+ | 15mg | Maximum dose (if tolerated) |
Important Notes:
- Minimum 4 weeks at each dose level before escalation
- Many protocols plateau at 10mg or 12.5mg
- Consider larger vials (10mg, 30mg) after initial titration phase
Injection Guide
Subcutaneous Administration
- Clean injection site with alcohol swab and let dry
- Pinch skin fold at abdomen, thigh, or upper arm
- Insert needle at 90° angle
- Inject slowly over 5-10 seconds
- Wait 10 seconds before withdrawing
- Apply gentle pressure — do not massage
Site Rotation
Rotate weekly between:
- Abdomen (preferred) — avoid 2-inch radius around navel
- Front/outer thigh
- Back of upper arm
Storage Requirements
Lyophilized (Powder Form)
- Temperature: -20°C (-4°F) or colder
- Duration: 2+ years
- Conditions: Protect from light and moisture
Reconstituted (Mixed with BAC Water)
- Temperature: 2-8°C (36-46°F)
- Duration: 4-6 weeks
- Conditions: Protect from light, never freeze
Research Considerations
Dual Mechanism of Action
Tirzepatide’s unique dual-receptor approach:
GIP Receptor Activation:
- Enhanced insulin secretion
- Improved beta-cell function
- Potential adipose tissue effects
GLP-1 Receptor Activation:
- Appetite suppression
- Delayed gastric emptying
- Glucagon suppression
When to Use 5mg Vials
The 5mg vial is recommended for:
- Initial research phases — Starting at 2.5mg dose
- Cost-conscious protocols — Testing tolerance before committing to larger quantities
- Short-term studies — 2-4 week initial assessments
For maintenance phases at higher doses, transition to 10mg or 30mg vials for cost efficiency.
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387:205-216.
- Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” N Engl J Med. 2021;385:503-515.
- Samms RJ, et al. “How May GIP Enhance the Therapeutic Efficacy of GLP-1?” Trends Endocrinol Metab. 2020;31:410-421.
Last updated: December 03, 2025
Disclaimer: This information is for educational and research purposes only. Tirzepatide as a research peptide is not intended for human consumption. Pharmaceutical tirzepatide (Mounjaro®, Zepbound®) requires a prescription. Always follow applicable laws and institutional guidelines.